Beijing Kawin Technology Adjusts Valuation Amidst Complex Financial Metrics and Challenges

Beijing Kawin Technology Share-Holding Co., Ltd., operating in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. The stock's valuation grade has been revised from very attractive to fair, reflecting a shift in its financial metrics. The company's P/E ratio stands at 120, indicating a significant valuation relative to earnings. Additionally, the Price to Book Value is recorded at 1.07, while the EV to EBIT is notably high at 558.28. The EV to EBITDA ratio is 28.75, and the EV to Sales ratio is 1.01, suggesting a complex financial landscape. The dividend yield is reported at 3.40%, with a return on capital employed (ROCE) of 0.20% and a return on equity (ROE) of 0.90%. Over the past five years, net sales have grown at an annual rate of 2.63%, while operating profit has seen a growth rate of 14.42%. Despite these figures, the company has faced challenges, including negative financial performance in the quarter ending March 2026 and underperformance compared to the China Shanghai Composite over various time frames. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.